Indoco Remedies Limited (INDOCO.BO)
INR 337.6
(-0.35%)
INR 337.6
(-0.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 17.89 Billion INR | 10.81% |
| 2022 | 16.4 Billion INR | 9.07% |
| 2021 | 15.03 Billion INR | 23.4% |
| 2020 | 12.18 Billion INR | 12.84% |
| 2019 | 10.79 Billion INR | 14.64% |
| 2018 | 9.42 Billion INR | -7.43% |
| 2017 | 10.17 Billion INR | -2.83% |
| 2016 | 10.47 Billion INR | 3.89% |
| 2015 | 10.08 Billion INR | 17.64% |
| 2014 | 8.56 Billion INR | 16.97% |
| 2013 | 7.32 Billion INR | 16.14% |
| 2012 | 6.3 Billion INR | 10.9% |
| 2011 | 5.68 Billion INR | 18.23% |
| 2010 | 4.81 Billion INR | 19.58% |
| 2009 | 4.02 Billion INR | 14.74% |
| 2008 | 3.5 Billion INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 3.25 Billion INR | 33.92% |
| 2005 | 2.43 Billion INR | 25.38% |
| 2004 | 1.94 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.31 Billion INR | -4.04% |
| 2024 Q2 | 4.32 Billion INR | 0.27% |
| 2023 Q2 | 4.73 Billion INR | 13.62% |
| 2023 Q1 | 4.16 Billion INR | -2.78% |
| 2023 FY | 18.17 Billion INR | 10.81% |
| 2023 Q4 | 4.49 Billion INR | -1.99% |
| 2023 Q3 | 4.58 Billion INR | -3.13% |
| 2022 FY | 16.4 Billion INR | 9.07% |
| 2022 Q1 | 3.95 Billion INR | -1.33% |
| 2022 Q2 | 4.04 Billion INR | 2.46% |
| 2022 Q3 | 4.11 Billion INR | 1.53% |
| 2022 Q4 | 4.28 Billion INR | 4.28% |
| 2021 Q2 | 3.72 Billion INR | -2.23% |
| 2021 Q1 | 3.81 Billion INR | 29.26% |
| 2021 FY | 15.03 Billion INR | 23.4% |
| 2021 Q3 | 3.48 Billion INR | -6.45% |
| 2021 Q4 | 4 Billion INR | 14.8% |
| 2020 FY | 12.18 Billion INR | 12.84% |
| 2020 Q1 | 2.66 Billion INR | 1.39% |
| 2020 Q4 | 2.95 Billion INR | -11.56% |
| 2020 Q3 | 3.33 Billion INR | 3.28% |
| 2020 Q2 | 3.23 Billion INR | 21.08% |
| 2019 FY | 10.79 Billion INR | 14.64% |
| 2019 Q3 | 2.83 Billion INR | -0.96% |
| 2019 Q1 | 2.47 Billion INR | 0.89% |
| 2019 Q4 | 2.63 Billion INR | -7.17% |
| 2019 Q2 | 2.86 Billion INR | 15.79% |
| 2018 Q3 | 2.48 Billion INR | 5.0% |
| 2018 Q1 | 2.12 Billion INR | 0.0% |
| 2018 FY | 9.42 Billion INR | -7.43% |
| 2018 Q4 | 2.44 Billion INR | -1.24% |
| 2018 Q2 | 2.36 Billion INR | 11.05% |
| 2017 FY | 10.17 Billion INR | -2.83% |
| 2016 FY | 10.47 Billion INR | 3.89% |
| 2015 FY | 10.08 Billion INR | 17.64% |
| 2014 Q1 | 1.98 Billion INR | 0.0% |
| 2014 FY | 8.56 Billion INR | 16.97% |
| 2013 Q1 | 1.53 Billion INR | -6.6% |
| 2013 FY | 7.32 Billion INR | 16.14% |
| 2012 Q4 | 1.64 Billion INR | 0.0% |
| 2012 FY | 6.3 Billion INR | 10.9% |
| 2011 FY | 5.68 Billion INR | 18.23% |
| 2010 FY | 4.81 Billion INR | 19.58% |
| 2009 FY | 4.02 Billion INR | 14.74% |
| 2008 FY | 3.5 Billion INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 3.25 Billion INR | 33.92% |
| 2005 FY | 2.43 Billion INR | 25.38% |
| 2004 FY | 1.94 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 57.482% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -324.815% |
| Sigachi Industries Limited | 3.98 Billion INR | -348.533% |
| Bal Pharma Limited | 3.39 Billion INR | -427.52% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -39.703% |
| Medico Remedies Limited | 1.44 Billion INR | -1134.779% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1615.1% |
| Venus Remedies Limited | 5.91 Billion INR | -202.553% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -2268.711% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1545.638% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -6.256% |
| Shilpa Medicare Limited | 11.51 Billion INR | -55.388% |
| Aarti Drugs Limited | 25.28 Billion INR | 29.231% |
| Lupin Limited | 200.1 Billion INR | 91.058% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 93.766% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 90.592% |
| Windlas Biotech Limited | 6.3 Billion INR | -183.609% |
| Suven Life Sciences Limited | 116.92 Million INR | -15203.73% |
| Eris Lifesciences Limited | 20.09 Billion INR | 10.935% |
| Valiant Laboratories Limited | 1.82 Billion INR | -882.905% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 48.641% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -44.498% |
| Ipca Laboratories Limited | 76.22 Billion INR | 76.524% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -132.322% |
| Achyut Healthcare Limited | 61.36 Million INR | -29058.855% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 96.31% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -277.985% |
| RPG Life Sciences Limited | 5.82 Billion INR | -207.439% |
| Mankind Pharma Limited | 103.34 Billion INR | 82.685% |
| Laurus Labs Limited | 50.01 Billion INR | 64.224% |
| Piramal Pharma Limited | 81.71 Billion INR | 78.1% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -590.257% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 83.127% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 70.723% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 84.852% |
| Unichem Laboratories Limited | 16.57 Billion INR | -7.966% |
| Sequent Scientific Limited | 13.69 Billion INR | -30.642% |
| Novartis India Limited | 3.35 Billion INR | -434.053% |
| Wanbury Limited | 5.75 Billion INR | -210.857% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -70.204% |
| Wockhardt Limited | 27.89 Billion INR | 35.839% |
| Themis Medicare Limited | 3.81 Billion INR | -368.736% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -757.419% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 73.303% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 21.626% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 93.59% |
| Divi's Laboratories Limited | 78.45 Billion INR | 77.19% |
| NATCO Pharma Limited | 40.02 Billion INR | 55.286% |
| Gufic Biosciences Limited | 8.06 Billion INR | -121.833% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 15.551% |
| Ind-Swift Limited | 5.02 Billion INR | -256.132% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -55.434% |
| FDC Limited | 19.42 Billion INR | 7.9% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -3448.982% |
| Granules India Limited | 45.06 Billion INR | 60.291% |
| Medicamen Biotech Limited | 1.79 Billion INR | -897.985% |
| Alkem Laboratories Limited | 126.67 Billion INR | 85.874% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -38.125% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -4369.68% |
| Brooks Laboratories Limited | 794.86 Million INR | -2151.274% |
| Megasoft Limited | 373.95 Million INR | -4685.226% |
| ZIM Laboratories Limited | 3.67 Billion INR | -387.025% |
| Strides Pharma Science Limited | 40.51 Billion INR | 55.828% |
| Neuland Laboratories Limited | 15.58 Billion INR | -14.813% |
| Morepen Laboratories Limited | 17.01 Billion INR | -5.144% |
| Hikal Limited | 17.84 Billion INR | -0.272% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 1.435% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1059.177% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -385.479% |
| Hester Biosciences Limited | 3.04 Billion INR | -487.579% |